

**AMENDMENTS TO THE CLAIMS**

This listing of the claims will replace all prior versions, and listings, of claims in this application.

1. **(Previously Presented)** A method of treating an inflammatory disorder in a patient comprising, the method comprising

administering to ~~[[a]]said patient suffering from an inflammatory disorder at least one treatment selected from the group consisting of: inducing ferritin in the patient; expressing ferritin in the patient; and administering a pharmaceutical composition comprising a pharmaceutically acceptable carrier, wherein said composition comprises and at least one of~~ heme oxygenase-1 (HO-1), bilirubin, biliverdin, ferritin, iron, desferoxamine, salicylaldehyde isonicotinoyl hydrazone, iron dextran, or apoferritin ~~to the patient~~, in an amount sufficient to treat the inflammatory disorder; and

wherein the inflammatory disorder is localized in the gastrointestinal tract.

2. **(Original)** The method of claim 1, wherein the treatment is inducing ferritin in the patient.

3. **(Cancelled)**

4. **(Original)** The method of claim 1, wherein the treatment is administering a pharmaceutical composition comprising HO-1 to the patient.

5. **(Original)** The method of claim 1, wherein the treatment is administering a pharmaceutical composition comprising biliverdin to the patient.

6. **(Original)** The method of claim 5, wherein the pharmaceutical composition is administered to the patient at a dosage of about 1 to 1000 micromoles/kg/day.

7. **(Previously Presented)** The method of claim 1, wherein the inflammatory disorder is ulcerative colitis.

8. **(Original)** The method of claim 1, wherein the treatment is administering a pharmaceutical composition comprising bilirubin to the patient.

9. **(Original)** The method of claim 1, wherein the treatment is administering a pharmaceutical composition comprising ferritin to the patient.

10. **(Original)** The method of claim 1, wherein the treatment is administering a pharmaceutical composition comprising desferoxamine (DFO) or salicylaldehyde isonicotinoyl hydrazone (SIH) to the patient.

11. **(Original)** The method of claim 1, wherein the treatment is administering a pharmaceutical composition comprising iron dextran to the patient.

12. **(Original)** The method of claim 1, wherein the treatment is administering a pharmaceutical composition comprising apoferritin to the patient.

13. **(Original)** The method of claim 2, wherein the ferritin is induced by administering iron to the patient.

14-16. **(Cancelled)**

17. **(Previously Presented)** The method of claim 1, wherein the inflammatory disorder is selected from the group consisting of: amoebic dysentery, bacillary dysentery, schistosomiasis, campylobacter enterocolitis, yersinia enterocolitis, enterobius vermicularis, radiation enterocolitis, ischaemic colitis, eosinophilic gastroenteritis, ulcerative colitis, indeterminate colitis, and Crohn's disease.

18. **(Previously Presented)** The method of claim 1, wherein the inflammatory disorder is ulcerative colitis.

19. **(Cancelled)**

20. **(Previously Presented)** The method of claim 1, further comprising the steps of inducing HO-1 in the patient, and administering a pharmaceutical composition comprising carbon monoxide to the patient.

21-62. **(Cancelled)**